FEDERAL TRADE COMMISSION v. CEPHALON, INC.
Case Number:
2:08-cv-02141
Court:
Nature of Suit:
Judge:
Firms
- Akerman LLP
- Axinn Veltrop
- Blank Rome
- Caesar Rivise
- Clark Hill
- Cleary Gottlieb
- Covington & Burling
- Cravath Swaine
- Davis Polk
- Debevoise & Plimpton
- Dechert LLP
- DLA Piper
- Eckert Seamans
- Faegre Drinker
- Freshfields
- Grabar Law
- Holland & Knight
- Jones Day
- Kenny Nachwalter
- Kirkland & Ellis
- Rakoczy Molino
- Ropes & Gray
- Stevens & Lee
- Weil Gotshal
- White and Williams
- White & Case
- WilmerHale
- Wilson Sonsini
Companies
- Abbott Laboratories
- Allergan PLC
- Almirall SA
- Anchen Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim Vetmedica Inc.
- Bristol-Myers Squibb Co.
- Cephalon Inc.
- Dr. Reddy's Laboratories Ltd.
- Endo International PLC
- Forest Laboratories Inc.
- Fresenius Medical Care AG & Co. KGAA
- GSK PLC
- Impax Laboratories, Inc.
- Johnson & Johnson
- King Pharmaceuticals Inc.
- Lupin Ltd.
- Merck & Co. Inc.
- Paddock Laboratories Inc.
- Par Pharmaceutical Cos. Inc.
- Pfizer Inc.
- Purdue Pharma LP
- Sumitomo Pharma America Inc.
- Teva Pharmaceutical Industries Ltd.
- Wockhardt Ltd.
- Wockhardt USA LLC
Government Agencies
Sectors & Industries:
-
October 13, 2021
Louisiana Can't Wade Into FTC's Settled Provigil Case
A Pennsylvania federal court on Wednesday rejected a bid from the state of Louisiana to intervene in a case over the alleged delay of generic versions of narcolepsy drug Provigil that the Federal Trade Commission settled with Teva through a $1.2 billion deal in 2015.
-
October 29, 2019
Allergan's $750M Deal Among Pharma's Top Antitrust Payouts
A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.
-
February 20, 2019
FTC's Teva Settlement A Sign Of Enforcement Evolution
The Federal Trade Commission's settlement this week with Teva Pharmaceuticals further winnows the types of deals the company can sign with would-be competitors and illuminates the agency's evolving approach to cases in which drug companies are accused of colluding to delay competition.
-
June 17, 2015
Judge OKs $1.2B Cephalon Deal In FTC Pay-For-Delay Suit
A Pennsylvania federal judge on Wednesday approved the Federal Trade Commission's record-setting $1.2 billion settlement with Cephalon Inc. in a long-running antitrust suit accusing the company of paying generic-drug makers to hold off on launching their own version of narcolepsy treatment Provigil.
-
May 28, 2015
Pay-For-Delay Questions Linger After $1.2B Cephalon Deal
The Federal Trade Commission's record-setting $1.2 billion settlement with Cephalon Inc. on Thursday gives the antitrust watchdog a boost as it continues to challenge so-called pay-for-delay settlements. But the eleventh-hour deal disappointed observers who had hoped for answers to lingering questions about how to prosecute the complex cases.
-
May 28, 2015
FTC's $1.2B Win Shows Pay-For-Delay Deals On Thin Ice
The Federal Trade Commission's $1.2 billion settlement with Cephalon Inc. over the company's huge payments to rivals is a fresh sign that so-called pay-for-delay deals involving big exchanges of money will be difficult to defend in the wake of a landmark U.S. Supreme Court decision from two years ago, experts say.
-
May 28, 2015
Paying The Price For Pay-For-Delay: Cephalon's 7-Year Saga
With a $1.2 billion settlement on Thursday ending the Federal Trade Commission’s long-running case against Cephalon Inc. for allegedly paying rivals to hold off selling generic versions of the narcolepsy drug Provigil, Law360 takes a look back at the seven-year antitrust fight.
-
May 28, 2015
FTC Health Care Chief: $1.2B Cephalon Deal A Strong Warning
Cephalon Inc.'s promise to settle patent litigation without using side deals to get reverse payments as part of a $1.2 billion agreement with the Federal Trade Commission sends a "strong and important" message to the rest of the industry to change its behavior, FTC health care chief Markus Meier told Law360 on Thursday.
-
May 28, 2015
Cephalon To Pay $1.2B To End FTC Pay-For-Delay Suit
Cephalon Inc. agreed Thursday to pay $1.2 billion to settle a long-running antitrust suit accusing the company of paying generic-drug makers to hold off on launching their own version of narcolepsy treatment Provigil, handing the Federal Trade Commission a major victory in its decadelong campaign against so-called pay-for-delay patent settlements.
-
April 16, 2015
FTC Can Seek Disgorgement In Cephalon Suit, Judge Says
The Federal Trade Commission can pursue billions of dollars Cephalon Inc. allegedly made through a series of pay-for-delay deals meant to stave off competition with its blockbuster narcolepsy drug, a Pennsylvania federal judge ruled Wednesday.